Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
30
9
2021
medline:
26
3
2022
entrez:
29
9
2021
Statut:
ppublish
Résumé
Persistence of the viral reservoir is the main barrier to curing HIV. Initiation of ART during acute HIV infection can limit the size and diversity of the reservoir. In depth characterization of the reservoir in individuals who initiate ART during acute infection will be critical for clinical trial design and cure strategies. Four cohorts with participants who initiated ART during acute infection or during chronic infection were enrolled in a cross-sectional, noninterventional study. Viral reservoir was evaluated by the Intact Proviral DNA Assay (IPDA), the Total HIV DNA Assay (THDA) and the Quantitative Viral Outgrowth Assay (QVOA). Viral diversity and susceptibility to V3-glycan bNAbs were determined by genotyping of the viral envelope gene. Participants who initiated ART during the acute Fiebig I-IV stages had lower level of total HIV DNA than participants who initiated ART during chronic infection whereas no difference was observed in intact HIV DNA or outgrowth virus. Participants who initiated ART during Fiebig I-IV also had lower viral diversity and appeared to have higher susceptibility to bNAbs than participants initiating ART during chronic infection. Individuals initiating ART during Fiebig I-IV had small viral reservoirs, low viral diversity, and high susceptibility to bNAbs, and would be an optimal target population for proof-of-concept HIV cure trials.
Identifiants
pubmed: 34586088
doi: 10.1097/QAD.0000000000003088
pii: 00002030-202202010-00006
doi:
Substances chimiques
Anti-Retroviral Agents
0
Broadly Neutralizing Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-214Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy . Nature 1999; 401:874–875.
Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, et al. RV411 study group. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection . Nat Med 2018; 24:923–926.
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy . Nat Med 1999; 5:512–517.
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy . Science 1997; 278:1295–1300.
Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells . Nat Med 2003; 9:727–728.
Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia . Science 1997; 278:1291–1295.
Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1 . J Infect Dis 2005; 191:1410–1418.
Kouyos RD, von Wyl V, Yerly S, Boni J, Rieder P, Joos B, et al. Swiss HIV Cohort Study. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection . Clin Infect Dis 2011; 52:532–539.
Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederost B, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection . PLoS One 2010; 5:e13310.
Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies . PLoS Pathog 2013; 9:e1003174.
Leyre L, Kroon E, Vandergeeten C, Sacdalan C, Colby DJ, Buranapraditkun S, et al. RV254/SEARCH010, RV304/SEARCH013, SEARCH011 study groups. Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection . Sci Transl Med 2020; 12:eaav3491.
Maldarelli F, Kearney M, Palmer S, Stephens R, Mican J, Polis MA, et al. HIV populations are large and accumulate high genetic diversity in a nonlinear fashion . J Virol 2013; 87:10313–10323.
Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection . AIDS 2003; 17:1871–1879.
Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication . Science 2014; 345:169–174.
Colby DJ, Sarnecki M, Barouch DH, Tipsuk S, Stieh DJ, Kroon E, et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption . Nat Med 2020; 26:498–501.
Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, et al. Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults living with human immunodeficiency virus-1 . Clin Infect Dis 2020; 72:e815–e824.
Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 . Nat Med 2016; 22:839–850.
Thomsen N, Balakrishnan M, Pace C, Zhang X, Hung M, Nagel M, et al. GS-9722: first-in-class, effector-enhanced, broadly neutralizing antibody for HIV cure [Poster 0356].Conference on Retroviruses and Opportunistic Infections (CROI) . Seattle, WA, 2019.
Ruane P, Daar E, Workowski K, Begley R, Humeniuk R, Makadzange T, et al. Safety & pharmacokinetics of GS-9722 In HIV-negative participants and people with HIV [presentation].Conference on Retroviruses and Opportunistic Infections (CROI) . Boston, MA, 2020.
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals . Nat Med 2017; 23:185–191.
Mahomed S, Garrett N, Baxter C, Abdool Karim QA, Abdool Karim SS. Clinical trials of broadly neutralizing monoclonal antibodies for HIV prevention: a review . J Infect Dis 2020; (in press).
Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses . Nature 2019; 566:120–125.
Simonetti FR, White JA, Tumiotto C, Ritter KD, Cai M, Gandhi RT, et al. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA . Proc Natl Acad Sci U S A 2020; 117:18692–18700.
Laird GM, Rosenbloom DI, Lai J, Siliciano RF, Siliciano JD. Measuring the frequency of latent HIV-1 in resting CD4(+) T cells using a limiting dilution coculture assay . Methods Mol Biol 2016; 1354:239–253.
Moldt B, Parvangada A, Martin R, Pace C, Balakrishnan M, Thomsen ND, et al. Evaluation of broadly neutralizing antibody sensitivity by genotyping and phenotyping for qualifying participants to HIV clinical trials . J Acquir Immune Defic Syndr 2021; 88:61–69.
Yang X, Charlebois P, Gnerre S, Coole MG, Lennon NJ, Levin JZ, et al. De novo assembly of highly diverse viral populations . BMC Genomics 2012; 13:475.
Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction endonucleases . Proc Natl Acad Sci U S A 1979; 76:5269–5273.
Cillo AR, Hong F, Tsai A, Irrinki A, Kaur J, Sloan DD, et al. Blood biomarkers of expressed and inducible HIV-1 . AIDS 2018; 32:699–708.
Falcinelli SD, Kilpatrick KW, Read J, Murtagh R, Allard B, Ghofrani S, et al. Longitudinal dynamics of intact HIV proviral DNA and outgrowth virus frequencies in a cohort of individuals receiving antiretroviral therapy . J Infect Dis 2020; 224:92–100.
Papasavvas E, Azzoni L, Ross BN, Fair M, Yuan Z, Gyampoh K, et al. Intact human immunodeficiency virus (HIV) reservoir estimated by the intact proviral DNA assay correlates with levels of total and integrated DNA in the blood during suppressive antiretroviral therapy . Clin Infect Dis 2021; 72:495–498.
Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, et al. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies . J Infect Dis 2015; 212:1361–1365.
Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro . J Infect Dis 2008; 197:411–419.
Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et al. Swiss HIV Cohort Study. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART . Nat Commun 2019; 10:3193.
Abrahams MR, Joseph SB, Garrett N, Tyers L, Moeser M, Archin N, et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation . Sci Transl Med 2019; 11:eaaw5589.
Peluso MJ, Bacchetti P, Ritter KD, Beg S, Lai J, Martin JN, et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy . JCI Insight 2020; 5:e132997.
Gandhi RT, Cyktor JC, Bosch RJ, Mar H, Laird GM, Martin A, et al. AIDS Clinical Trials Group A5321 Team. Selective decay of intact HIV-1 proviral DNA on antiretroviral therapy . J Infect Dis 2021; 223:225–233.
Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malincarne L, et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients . Thromb Haemost 2013; 110:349–357.
Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, et al. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA) . Nat Commun 2021; 12:165.
Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, et al. BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection. Recommendations for measuring HIV reservoir size in cure-directed clinical trials . Nat Med 2020; 26:1339–1350.
Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys . Nature 2018; 563:360–364.
Mercado N, Chandrashekar A, Borducchi E, Nkolola J, Geleziunas R, Carr B, et al. PGT121 and vesatolimod in chronically treated SHIV-infected Rhesus monkeys [Poster].Conference on Retroviruses and Opportunistic Infections (CROI). Boston, Massachusetts; 2020.
Barouch D, Mercado N, Chandrashekar A, Borducchi E, Nkolola J, Pau M, et al. Combined active and passive immunization in SHIV-infected rhesus monkeys.Conference on Retroviruses and Opportunistic Infections . Boston, MA; 2020.
Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies . Nature 2014; 509:55–62.
Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus . Nature 2013; 496:469–476.
Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, et al. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody . Cell 2016; 165:449–463.
Lee GQ, Reddy K, Einkauf KB, Gounder K, Chevalier JM, Dong KL, et al. HIV-1 DNA sequence diversity and evolution during acute subtype C infection . Nat Commun 2019; 10:2737.